Teva's Ajovy may have been rejected by Express Scripts for reimbursement but other US health insurers will accept it, say the analysts.
The Israeli stem cell cancer therapy developer will hold the offering at a company valuation of $275 million.
Express Scripts has endorsed coverage of competing migraine drugs made by Amgen and Eli Lilly.
The Asana Bio Group Israeli holding company has invested $2.3 million in founding a laboratory for research on the active ingredients in the cannabis plant.
The Israeli company, which has developed a minimally invasive way to replace the tricuspid heart valve, is aiming at a $6 billion market.
BOL produces and markets cannabis for the Israeli market.
The US Court of Appeals for the Federal Circuit upheld a 2017 decision by a Delaware court canceling four patents on the 40 mg version of Teva's blockbuster multiple sclerosis treatment.
The companies have entered into a clinical trial collaboration to evaluate Compugen’s COM701 with BMS's PD-1 immune checkpoint inhibitor Opdivo, in patients with advanced solid tumors.
If the FDA approves CT-P10 for marketing, this will be the first biosimilar generic version of Rituxan.
Murray Kessler is replacing Uwe Roehrhoff, who lasted 10 months in the job.
Medtronic is buying Prof. Moshe Shoham's Mazor for $1.6 billion, while he is looking forward to more robots and more startups.
Teva loses another Copaxone patents case